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Abstract
Background: Impairment of visual cognition occurs in up to 25% of patients with MS, however data on
progressive disease is limited and the neural basis remains unknown.
Objective: To evaluate the influence of multifocal inflammatory CNS white matter demyelination burden on visual
cognition in equivalent SPMS and PPMS cohorts.
Methods: 59 SPMS and 27 PPMS patients matched for demographic and disease characteristics were evaluated
using visuospatial and visuoperceptual components of the Addenbrooke’s cognitive examination-revised (ACE-R)
battery. Factors influencing performance were then identified by logistic regression. Exploratory logistic models were
also used to determine the predictive value of deficits in attention, working memory, and arithmetic abilities. Finally,
comparison of deficits between equivalent primary (PPMS) and secondary (SPMS) progressive disease groups was
used to evaluate a potential dose-response for cumulative multifocal inflammatory CNS white matter demyelination.
Results: The overall prevalence of impairment in visual cognition was 14.0% (95%CI=6.4 to 21.4%) with no
difference between disease groups. Qualitatively, the observed deficits in visual cognition were subtle, and patients
were not able to predict them. Impairment was more common in women (OR 3.2; 95% CI=0.8 to 13.2), and subjects
with a Beck depression inventory II score ≥ 25 (OR 5.2; 95% CI=1.1 to 24.2). No effect was seen for: age, years in
full-time education, disease duration, clinical evidence of anterior visual pathway dysfunction, or motor disability.
Exploratory analyses showed no predictive association with deficits in attention or working memory, however
impairment of basic arithmetic skills was a highly significant predictor of impaired visual cognition (OR 29.4, 95% CI
3.0 to 291.9). Allowing for all significant predictors, secondary and primary progressive disease groups had
equivalent rates of impairment (OR 1.6, 95% CI 0.4 to 7.1; p=0.538).
Conclusions: Impairment of visual cognition in progressive MS is more common in women and patients with
high levels of depressive symptomatology, but occurs independently from anterior visual pathway dysfunction and
the cumulative burden of inflammatory CNS white matter demyelination. These findings suggest that the site rather
than the absolute quantity of brain pathology is crucial, with the strong association observed to impairment of basic
arithmetic skills implicating possible localization to the intraparietal sulcus.
Keywords: Brain diseases; Demyelinating diseases; Multiple
sclerosis, Chronic progressive; Multiple sclerosis, Secondary
progressive; Multiple sclerosis, Primary progressive; Cognition;
cognition disorders; Cognitive science; Visual pathways; Parietal lobe
Introduction
Cognitive impairment occurs in 42-70% of people with multiple
sclerosis (pwMS), with deficits most frequently described, in complex
attention, efficiency of information processing, executive functioning,
processing speed, and long-term memory [1]. Although impairment of
visual cognition in pwMS has received comparatively less attention, it
is present in up to 25% of subjects [2]. Moreover, deficits in visual
cognition are not secondary phenomena due to disease involving the
anterior visual pathways and associated (simple) perceptual
impairment [3], nor explained as part of a universal impairment of
cognitive abilities in MS [4].The real-world consequence of such
deficits can be highly significant, as demonstrated by the observation
that impaired visual learning and memory in pwMS is the strongest
predictor of traffic violations and collisions [5]. Crucially, these deficits
may be under-recognised in clinical practice as they occur
independently to more commonly evaluated frontal-executive abilities
[6].
Despite awareness that visual cognitive functions are frequently
impaired in MS, the neural basis of clinical deficits remains unknown
[4]. Increasing recognition of both inflammatory and
neurodegenerative components in MS pathology [7]-the latter of
particular salience in progressive disease-raises the question to what
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extent clinical deficits reflect archetypal multifocal inflammatory
demyelination in CNS white matter, or alternative pathogenic
processes such as grey matter inflammatory demyelination and/or
neuroaxonal loss [8]. Determining the role of these pathogenic
processes is particularly challenging given that imaging biomarkers are
currently able to offer only general insights; measures of brain atrophy
or white matter T2 hyperintense lesions lack pathological specificity
[9], and less than 20% of grey matter lesions are detectable by the most
sensitive contemporary (double-inversion recovery) MR techniques
[10]. An alternative strategy to evaluate the effects of pathological
processes on cognitive impairment is the comparison of MS patient
groups who differ in their dominant brain pathology. Patients with
primary progressive MS (PPMS) are characterized by the steady
accumulation of fixed disability from onset and have minimal levels of
multifocal inflammatory CNS white matter demyelination [11]. In
contrast, patients with secondary progressive MS have high levels
throughout their disease course [12,13]. Detailed clinical phenotyping
of patients with a well-established disease course therefore allows
evaluation of a potential “dose-response” between multifocal
inflammatory CNS white matter demyelinating pathology and clinical
features.
Like other cognitive functions, the evaluation of visual cognition in
MS is challenging due to a wide range of potentially confounding
factors. Weakness, ataxia, spasticity, and other physical manifestations
limit performance on tasks involving copying or drawing (Figure 1). In
addition, reduced information processing speed affects performance
on timed tasks [14]; dysarthria on tasks requiring verbal responses;
and deficits of memory, attention, and executive functions have the
potential to impact on any complex task. Components of the
Addenbrooke’s Cognitive Examination (ACE-R) that have been
adapted from the Visual Object and Space Perception (VOSP) battery
offer an opportunity to minimize the contribution of these factors
[15,16]. Furthermore, the dot counting and incomplete letter
recognition tasks in the ACE-R provide a differential assessment of
function in the dorsal and ventral visual processing streams
respectively [17]. We therefore used these simple visual cognition tasks
that are robust to motor and other physical deficits, and compared
performance between MS patient groups with high (SPMS) and low
(PPMS) levels of multifocal inflammatory CNS white matter
demyelination. Our aim was to test a prediction that the rate of
impairment in visual cognition would be equivalent between SPMS
and PPMS groups, indicating that the cumulative burden of multifocal
inflammatory demyelination in the CNS white matter did not play a
pathogenically significant role.
Figure 1: Clock drawing test impairment with and without motor disability of dominant hand. Clock drawing test impairment is shown for
two patients with progressive MS. Patients were instructed to “draw a clockface with both numbers and hands, showing the time as ten past
five”. Panel A shows a patient with normal dominant hand motor function. Panel B shows a patient with impairment of dominant hand
motor function.
Methods
Participants
Participants were recruited from a UK hospital-based MS clinic.
Eligibility criteria were: revised (2010) McDonald Criteria MS [18];
progressive disease course; logMAR visual acuity <0.2 in at least one
eye (equivalent to 6/9 or better on Snellen); and the absence of an
additional major affective, psychiatric, or neurological disorder.
Approval was obtained from the local ethics committee, and all
patients gave written informed consent.
Tests and procedures
Patients were assessed at a single visit in a hospital setting through
neurological history and examination including: multiple sclerosis
impact scale-29 (MSIS-29), expanded disability status scale (EDSS),
the multiple sclerosis functional composite (MSFC), Beck depression
inventory–II (BDI-II), Addenbrooke’s cognitive examination
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(Revised) (ACE-R) and the 3-second paced auditory serial additions
test (PASAT). Subjects were asked if they thought they had cognitive
impairment by the question “do you suffer from problems with your
memory or concentration”. Clinical evidence of disease involving the
anterior visual pathway was defined as the presence of one or more of
the following: clinical history consistent with optic neuritis, optic
atrophy, an afferent pupillary defect, or an abnormality of visual
evoked responses consistent with demyelination. Visual assessment
tasks were performed binocularly using the subject’s optimum
refractive correction. All assessments were administered by a single
observer (PC) who was blinded to the patient’s disease course. Two
ACE-R tasks that are robust to confounding by motor or other
cognitive deficits were used to evaluate visual cognition: dot counting
and incomplete letters [16]. Both tasks comprise four elements. For the
dot counting task, two odd-number and two even-number elements
were presented, and the subject instructed to count and report the
total number of dots in each element. For the incomplete letters task,
the letters K, M, A, & T were presented in a sans-serif font with
multiple edge segments missing. Subjects were asked to report the
letters shown. Both tasks are untimed and do not require a motor
response.
Statistical analysis
Cognitive impairment for the PASAT, ACE-R, and visual cognition
tasks was defined by scores less than two standard deviations from the
mean of published age-matched norms [2,15,16]. Potential
explanatory/confounding factors were assessed by logistic regression.
The sum of ACE-R dot counting and incomplete letters test scores was
used to provide a composite assessment of function in the post-
primary visual cortex pathways. Model selection was achieved through
a forward stepwise selection procedure with initial covariates of: age,
sex, years of education, MS disease duration, clinical evidence of
anterior visual pathway dysfunction, motor function in the dominant
hand-assessed by time in minutes to complete the nine-hole peg test
(NHPT), and depression (defined as a BDI-II score ≥ 25). Covariates
were retained if significant at the 20% level. This model was then
compared to a second model that included an indicator variable for
disease group (SPMS vs. PPMS). Improvement in model fit (model
two over model one) was assessed by the likelihood ratio test. The 95%
confidence interval for the odds ratio of cognitive impairment due to
SPMS in the second model was then used to evaluate equivalence
between groups. An upper limit for δ (OR) of 8.9 was pre-defined as
this represents the observed ratio of white matter lesions in SPMS
compared to PPMS [19].
Results
Recruitment, data completeness, and participant
characteristics
Ninety-two patients were screened for eligibility. After evaluation,
six patients were excluded due to lack of a definite progressive disease
course. Fifty-nine patients with SPMS and twenty-seven with PPMS
were therefore recruited. Seven patients were unable to perform the
nine-hole peg test due to severe motor disability in their dominant
upper limb and ten patients declined to perform the PASAT. Timing
for disease onset could not be defined for two patients with PPMS, and
seven patients did not provide a response to the question regarding
subjective cognitive impairment (3/59 [5.1%] SPMS group vs. 4/27
[14.8%] PPMS group; p=0.1257). Data ascertainment was complete for
all other assessments.
Clinical evidence of disease involving the anterior visual pathway
was seen in both disease groups, although more frequently in the
SPMS group (25/59 [42.4%] SPMS vs. 2/27 [7.4%] PPMS; p=0.001).
No other differences were seen between groups in demographic or
disease characteristics (Table 1). Ten SPMS patients were classified as
cognitively impaired on PASAT (10/59 [17.0%] of the total SPMS
group; 10/53 [18.9%] of those who performed the task), and fifteen on
the ACE-R (15/59 [25.4%]). Six PPMS patients were classified as
cognitively impaired on the PASAT (6/27 [22.2%] of the total PPMS
group; 6/23 [26.1%] of those who performed the task), and three on
the ACE-R (3/27 [11.1%]).
Patient group
SPMS PPMS p
n 59 27 -
Age (mean, SD) 50.4 (8.6) 53.6 (9.7) 0.127
Male sex (%) 55.9 59.3 0.773*
Years of education (mean, SD) 13.3 (3.2) 12.6 (2.7) 0.319
Disease duration (mean, SD) 13.2 (7.7) 10.3 (5.9) 0.094
EDSS (mean, SD) 5.9 (1.1) 5.5 (1.5) 0.188
MSIS-29 – total (mean, SD) 87.1 (20.9) 78.7 (20.6) 0.088
MSIS-29 – physical (mean, SD) 63.9 (16.1) 58.4 (14.9) 0.139
MSIS-29 – psychological (mean,
SD)
22.8 (7.7) 20.2 (8.0) 0.163
BDI-II score (mean, SD) 14.7 (9.6) 12.6 (8.7) 0.284
Clinical evidence of disease
involving the anterior visual
pathway (%)
42.4 7.4 0.001*
Subjective cognitive impairment
(%)
66.1 43.5 0.063*
PASAT score (mean, SD) 38.4 (11.9) 37.6 (14.2) 0.802
Total ACE-R score (mean, SD) 91.5 (7.8) 92.1 (4.0) 0.435
Table 1: Subject characteristics by disease course. SPMS: Secondary
Progressive MS; PPMS: Primary Progressive MS; MSIS-29: Multiple
Sclerosis Impact Scale 29; EDSS: Expanded (Kurtzke) Disability Status
Scale; BDI-II: Beck Depression Inventory (II); PASAT: Paced Auditory
Serial Additions Test. Significance tests by Student’s t-test or (*)
Fisher’s exact test.
Performance on visual cognition tasks
The overall prevalence of visual cognition dysfunction assessed by
the combined score for dot counting and incomplete letter tests was
14.0% (95% CI=6.5 to 21.4%), with no difference between SPMS (9/59
[15.3%]) and PPMS (3/27 [11.1%]) groups (p=0.607). Impairment on
the dot counting test was seen in 12.9% (95% CI=6.6% to 22.0%) of the
total cohort, whereas impairment on the incomplete letters test was
seen less frequently (1.1%; 95% CI=0.03% to 6.4%; p=0.003). The
severity of impairment on either task was subtle: one sixty-two year
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old female with PPMS and no evidence of anterior visual pathway
dysfunction responded incorrectly in two (2/4) dot counting elements,
the remainder of patients who made errors failed on only one element.
All patients who made errors on the incomplete letters test failed only
one (1/4) element. The absolute magnitude of errors on the dot
counting tasks was also small, with all erroneous responses within one
integer of the correct score.
Predictors of performance on visual cognition tasks
Logistic regression was then used to evaluate the influence of
demographic and disease characteristics on visual cognition
performance. Forward stepwise selection established a best-fit model
that included: female sex (OR 3.2; 95% CI=0.8 to 13.2) and BDI-II
score ≥ 25 (OR 5.2; 95% CI=1.4 to 36.8). No effect was seen for: age,
years of education, MS disease duration, clinical evidence of anterior
visual pathway dysfunction, or motor function in the dominant hand
assessed by time in minutes to complete the nine-hole peg test
(NHPT). When asked about memory or concentration difficulties,
patients were unable to predict their visual cognition performance
(expected agreement 43.4%, observed agreement 43.0%, κ=- 0.01).
Moreover, this question also resulted in poor prediction of impaired
performance on the two “global” measures of cognition: PASAT
(expected agreement 44.1%, observed agreement 54.4%, κ=0.18) and
total ACE-R score (expected agreement 44.8%, observed agreement
55.7%, κ=0.20).
To investigate a potential confounding effect of attentional deficits
on visual cognition task performance, subjects with possible
impairment of attention (defined as any score below ceiling [<18/18]
on the ACE-R attention domain) were identified (n=20). Of the twelve
patients with visual cognition impairment, four (4/12) also had
attentional performance below ceiling. Agreement between attentional
and visual cognition impairment was poor (expected agreement
69.3%, observed agreement 72.1%, κ=0.09). Then, in order to examine
the possibility that attentional deficits might alter the influence on
visual cognition task performance of significant covariates (female sex
and BDI-II scores ≥ 25), regression analysis was repeated following the
addition of an indicator term for possible impairment of attention. No
significant effect of possible impairment of attention was seen (OR 1.4;
95% CI 0.3 to 5.8) and the best-fit model was unchanged. Finally, a
sensitivity analysis was performed by repeating the primary regression
model after exclusion of subjects with possible impairment of
attention (resultant n=66). Using this approach, two covariates were
retained with significance at the 20% level, although neither was
significant at the 5% level: years of education (OR 1.2 [per year] 95%
CI 0.9 to 1.5) and BDI-II score ≥ 25 (OR 5.4, 95% CI 0.9 to 31.9).
To investigate a potential confounding effect of working memory
deficits on visual cognition performance, subjects with possible
impairment of working memory (defined as performance below
ceiling [<5/5] on a 5-letter reverse word spelling task) were identified
(n=13). Of the twelve patients with visual cognition impairment, one
(1/12) also had working memory performance below ceiling.
Agreement between working memory and visual cognition
impairment was poor (expected agreement 72.5%, observed agreement
69.7%, κ=- 0.10). Repetition of the regression analysis with an
indicator term for impaired working memory showed no significant
effect (OR 0.4, 95% CI 0.0 to 3.3) and the best-fit model was
unchanged). Effects of working memory impairment on the dot
counting and incomplete letter recognition test scores were also
differentially examined because of the potential for a greater impact on
the dot counting performance. One patient (1/11) had impairment of
working memory in addition to impairment on the dot counting test;
agreement was again therefore poor (expected agreement 73.4%,
observed agreement 71.1%, κ=- 0.09). The single patient with
impairment on the incomplete letter recognition test had no evidence
of impaired working memory.
Two principle strategies were observed during performance of the
dot-counting task (Figure 2). Namely, progressive visual inspection of
the test area with sequential addition of dots as they were encountered
(ie. 1,2,3,4… x), or visual inspection of the test area by sub-sections
that contain clusters of dots with subsequent addition of the cluster
scores (e.g. 2+3 +4). Subjects who have poor basic arithmetic skills
may have therefore experienced difficulty with either strategy. The
presence of acalculia was therefore explored by performance on a
serial subtraction test (five subtractions of seven from an initial value
of 100). Although frequently viewed as a test of concentration,
performance on the familiar “serial sevens test” is almost entirely
determined by arithmetic skills [20]. Subjects with possible acalculia
(n=29) were identified by scores below ceiling (<5/5). Using this
definition, nine (9/11) patients with impaired performance on the dot
counting test also had possible acalculia. Despite the significant
proportion of patients with dot counting impairment who had
concomitant acalculia, the large number of patients with possible
acalculia but no impairment of dot counting (20/75) was reflected by
only modest agreement (expected agreement 62.1%, observed
agreement 74.4%, κ=0.33). A more stringent definition for possible
acalculia (<4/5) was therefore explored. Using this definition, five
(5/11) subjects with impairment of dot counting also had possible
However, the number of patients with possible acalculia but
normal dot counting remained high (10/75) and agreement was
therefore lower than with the original definition (expected agreement
74.2%, observed agreement 81.4%, κ=0.28). Repetition of the
regression analysis for total visual cognition performance (dot
counting and letter recognition) following addition of an indicator
term for possible acalculia (defined as performance below ceiling on
the serial subtraction test), showed a highly significant effect of
possible acalculia (OR 29.4, 95% CI 3.0 to 291.9) with a new best-fit
model that also included the two covariates previously identified:
female sex (OR 3.4, 95% CI 0.7 to 17.4) and BDI-II score ≥ 25 (OR
20.1, 95% CI 1.9 to 217.7).
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acalculia
Figure 2: Principal strategies for dot counting task performance. The two principal strategies observed for performing the dot counting test
are shown. Patients were asked to count the number of dots in the box without pointing to them. Panel A shows the visual stimulus. Panel B
shows a strategy of progressive visual inspection of the test area with sequential addition of dots as they were encountered (patients choosing a
“route” of visual scanning according to personal preference). Panel C shows a strategy of visual inspection of the test area by sub-sections that
contain clusters of dots (patients defining clusters according to personal preference) with subsequent requirement for addition of the segment
totals.
Figure 3: Performance on visual cognition tasks by disease group.
Individual subject performance on visual cognition tasks (sum of
incomplete letter test and dot counting scores) are shown by disease
group and disease duration, with the lower limit of normal (2
standard deviations below the control mean) indicated by dashed
lines. Males are shown as triangles, females as circles. Subjects with
a Beck depression inventory-II score ≥ 25 are shown as hollow-
markers. PPMS: Primary Progressive MS; SPMS: Secondary
Progressive MS. Impairment in seen in both SPMS and PPMS
groups, affecting individuals from both sexes, with or without
significant levels of depression.
The influence of disease group on visual cognition
performance
Impairment on visual cognition tasks was seen in both disease
groups at all stages of disease (Figure 3). Addition of an indicator term
for SPMS/PPMS status to the best-fit logistic regression model showed
no improvement in model fit (δ McFadden’s r2=0.009; p=0.80). The
95% confidence interval upper-bound estimated for the odds ratio
reflecting SPMS (ie. compared to PPMS and adjusted for sex, BDI-II
score ≥ 25, and acalculia) was within the pre-defined limit to
demonstrate equivalence (OR 1.6, 95% CI 0.4 to 7.1; p=0.538) (Figure
4).
Figure 4: Difference in odds of impaired visual cognition by disease
group. The odds ratio and 95% confidence interval (CI) is shown
for impaired visual cognition in the SPMS group (referenced to the
PPMS group). Pre-defined equivalence bounds are also shown by
the dashed lines (see text). The odds ratio 95% CI upper bound did
not cross the limit for equivalence, indicating that impairment of
visual cognition was not more frequent in the SPMS group.
Discussion
We found that deficits of visual cognition were present in 14% of
subjects, with assessment of dorsal visual stream (“where”) functions
identifying a significantly higher proportion of impairment (12.9%)
than assessment of ventral visual stream (“what”) functions (1.1%).
Clinical deficits of the anterior visual pathways were seen in 31.4% of
subjects, comparable to descriptions in recent targeted epidemiological
studies [21], however these did not predict impairment of visual
cognition. In contrast, impairment of visual cognition was strongly
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associated with acalculia and high self-reported depressive
symptomatology; female-sex was a possible further independent risk
factor. Finally, risk of visual cognitive impairment was not influenced
by the overall quantity of CNS white matter pathology-as indicated by
the absence of a dose response comparing SPMS to PPMS groups.
Few prior studies have compared cognitive impairment across MS
patient subgroups. In the largest, Huijbregts et al. used the Brief
Repeatable Battery of Neuropsychological Tests (BRB-N) to examine
71 patients with SPMS and 55 with PPMS [23]. Patients with SPMS
performed significantly more poorly than those with PPMS on the
10/36 spatial recall test (SRT) for both immediate and delayed recall
tasks. However, this finding cannot be confidently attributed to a
differential rate of impairment in visual cognition. Although intact
visual cognition is necessary for success in the 10/36 SRT, a wide range
of specific cognitive deficits may also cause impaired performance;
these include deficits in attention, visual perception, visuospatial
(dorsal stream) function, working memory, visual learning (encoding),
and visual recall (memory). Indeed, the application of cognitive tests
requiring complex and multi-domain cognitive integration has
consistently been demonstrated to detect higher rates of impairment
in SPMS cohorts compared to PPMS and relapsing remitting MS
(RRMS). This is unsurprising given that the cumulative burden of
brain pathology is highest in SPMS, and provides support for the case
to consider using cognitively complex-albeit simple to administer-
tasks as metrics of cumulative disease burden in pwMS, avoiding the
limitations of predominantly motor metrics, or the practical challenges
of imaging based approaches. However, such cognitively complex
tasks are of more limited value in cognitive psychology and cognitive
neuroscience due to difficulties with isolating the specific cognitive
deficit under investigation. This issue led Huijbregts et al. to conclude
that it would be useful to pursue the strategy of comparing MS patient
subgroups “with simpler tasks measuring for example only
information processing speed or visuospatial processing”.
Despite the simplicity of visual cognition tests used in our study,
potential confounding by other cognitive deficits remained possible.
Exploratory regression modeling showed no significant predictive
value of attentional or working-memory deficits on visual cognition
performance. However, the presence of acalculia was a strong
predictor of impairment. Given that the majority of visual cognition
deficits present were seen on the dot counting test, it is possible that
this observation either represents a causal association based on
inability to perform dot counting due to acalculia, or codependence
mediated by an external factor (e.g. parietal lobe pathology) with
effects on both arithmetic ability and dorsal visual stream functions.
The modest agreement seen between acalculia and visual cognition
impairment confirms functional dissociation, however only two (2/12)
subjects with visual cognition impairment did not have concomitant
acalculia and the negative predictive value of acalculia with respect to
visual cogniton impairment was therefore high (96.5%). The
possibility of codependence in MS due to pathology involving brain
regions that mediate both functions-in particular the intraparietal
sulcus [24] is further supported by the recently described association
between dorsal visual stream dysfunction and developmental
dyscalculia [25,26].
In addition to impaired arithmetic performance, two further
covariates were predictors of impaired visual cognition: female sex and
a high level of depressive symptomatology reported on the Beck
depression inventory II (BDI-II ≥ 25). Sex-based differences in visual
cognition task performance are a frequently reported finding, although
the method of test administration may have an impact on the
magnitude of differences observed [27]. In contrast, the relationship
between depression and impaired visual cognition is less clear. Our
findings are notably different from those seen in patients with “pure”
affective disorder (ie. subjects without MS) where ACE-R visuospatial
domain scores did not differ from healthy controls [28]. This
observation argues against an interpretation that impaired visual
cognition in our cohort can be causally attributed to comorbid
depression. Given that the BDI-II has been validated as an appropriate
marker of depression in pwMS [29], possible explanations for the
strong association in our study therefore include a causal link in the
reverse direction (ie. impairment of visual cognition resulting in
increased depressive symptomatology), or shared variance due to the
influence of an external factor. Although the latter is at face value
more likely, no plausible candidates currently exist for a shared
neuroanatomical or functional locus encompassing both visual
cognition and affective functions. Regional atrophy imaging studies of
MS patients with and without depression have reported conflicting
results, however frontal and temporal lobe pathology appear as the
most consistent associations [30–32]. The possibility that impairment
of visual cognition may have predisposed to depression in our cohort
is therefore worthy of consideration, and would be consistent with
previous reports of an interaction between cognitive impairments and
either high levels of avoidance coping or low levels of active coping
[33]. Finally, no effect on visual cognition task performance was seen
in our study for disease involving the anterior visual pathways, disease
duration, motor disability, or years of education. Moreover, patients
were unable to predict their performance when a generic “cognitive
impairment” question from the 29-Item Multiple Sclerosis Impact
Scale (MSIS-29) was used. It is possible that this question lacked
specificity for symptoms relevant to visual cognition, or that insight
into clinical deficits is limited-a phenomenon recently described with
high prevalence in patients with MS [34].
To evaluate the relationship between visual cognition and
multifocal inflammatory CNS white matter disease, a dose response
was hypothesized: if pathogenically relevant, a higher frequency of
impairment in subjects with SPMS (“high dose”) than those with
PPMS (“low dose”) would be predicted. This relationship was not
found, suggesting that the site of MS brain pathology may be crucial
rather than the total quantitative burden of pathology. This
interpretation would reconcile our findings with those of Stankiewicz
et al. who recently reported strong correlation (r=-0.70) in patients
(n=24) with predominantly (>80%) relapsing-remitting disease
between impairment on the JLO task and total fluid-attenuated
inversion-recovery (FLAIR) brain lesion volume on MR imaging [35].
Further research combining neuroimaging with comprehensive
assessment of visual cognition to test this hypothesis is therefore
supported.
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